[{"id":"06e22114-2e9b-44ef-aeef-5965af238d91","acronym":"","url":"https://clinicaltrials.gov/study/NCT06014762","created_at":"2023-08-28T14:08:43.980Z","updated_at":"2024-07-02T16:34:59.518Z","phase":"Phase 1","brief_title":"P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies","source_id_and_acronym":"NCT06014762","lead_sponsor":"Poseida Therapeutics, Inc.","biomarkers":" CD20 • CD5 • FCER2","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RG6540 • rimiducid (AP1903)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 04/16/2024","start_date":" 04/16/2024","primary_txt":" Primary completion: 03/01/2029","primary_completion_date":" 03/01/2029","study_txt":" Completion: 03/01/2041","study_completion_date":" 03/01/2041","last_update_posted":"2024-06-03"},{"id":"b73496d5-e698-47e5-b7a2-1ea85e0d187e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03696784","created_at":"2021-01-18T18:07:07.182Z","updated_at":"2024-07-02T16:35:07.400Z","phase":"Phase 1","brief_title":"Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma","source_id_and_acronym":"NCT03696784","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" ALK • BCL2 • BCL6 • IRF4","pipe":" | ","alterations":" ALK positive • BCL6 rearrangement • BCL2 rearrangement","tags":["ALK • BCL2 • BCL6 • IRF4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • bendamustine • fludarabine IV • Belrapzo (bendamustine RTD) • cyclophosphamide intravenous • rimiducid (AP1903)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/12/2019","start_date":" 03/12/2019","primary_txt":" Primary completion: 03/22/2027","primary_completion_date":" 03/22/2027","study_txt":" Completion: 03/22/2043","study_completion_date":" 03/22/2043","last_update_posted":"2024-04-26"},{"id":"494a3a47-09dc-456f-a62d-fc7e845bfb64","acronym":"","url":"https://clinicaltrials.gov/study/NCT03016377","created_at":"2021-01-18T14:50:40.602Z","updated_at":"2024-07-02T16:35:08.102Z","phase":"Phase 1/2","brief_title":"Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL","source_id_and_acronym":"NCT03016377","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" ABL1 • BCR • CD19","pipe":" | ","alterations":" CD19 positive • CD19 expression","tags":["ABL1 • BCR • CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous • iC9-CAR19 cells • rimiducid (AP1903)"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 03/22/2012","start_date":" 03/22/2012","primary_txt":" Primary completion: 04/22/2026","primary_completion_date":" 04/22/2026","study_txt":" Completion: 04/22/2041","study_completion_date":" 04/22/2041","last_update_posted":"2024-04-23"},{"id":"3914247b-96ea-451f-8ee1-b8dc8967ecc5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06066424","created_at":"2023-10-04T15:10:44.941Z","updated_at":"2024-07-02T16:35:18.780Z","phase":"Phase 1","brief_title":"Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)","source_id_and_acronym":"NCT06066424","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EGFR • HER-2 • PD-L1 • BRAF • ALK • ROS1 • NTRK • TACSTD2","pipe":" | ","alterations":" PD-L1 expression • BRAF V600E • HR positive • HER-2 negative • BRAF V600 • TROP2 expression","tags":["EGFR • HER-2 • PD-L1 • BRAF • ALK • ROS1 • NTRK • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF V600E • HR positive • HER-2 negative • BRAF V600 • TROP2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TROP2-CAR-NK • rimiducid (AP1903)"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 10/24/2023","start_date":" 10/24/2023","primary_txt":" Primary completion: 04/30/2038","primary_completion_date":" 04/30/2038","study_txt":" Completion: 04/30/2040","study_completion_date":" 04/30/2040","last_update_posted":"2024-02-19"},{"id":"faadd5d4-3c80-4487-b26e-e3f81311dd1e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02792114","created_at":"2021-01-18T13:42:21.295Z","updated_at":"2024-07-02T16:35:44.191Z","phase":"Phase 1","brief_title":"T-Cell Therapy for Advanced Breast Cancer","source_id_and_acronym":"NCT02792114","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2 • PD-L1 • MSLN","pipe":" | ","alterations":" HER-2 negative • MSLN expression","tags":["HER-2 • PD-L1 • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • cyclophosphamide intravenous • rimiducid (AP1903)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 186","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2023-06-30"},{"id":"083ff2b4-1c8e-4316-85e8-ab1466391065","acronym":"","url":"https://clinicaltrials.gov/study/NCT03301168","created_at":"2021-01-18T16:18:29.964Z","updated_at":"2024-07-02T16:36:07.482Z","phase":"Phase 1/2","brief_title":"Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant","source_id_and_acronym":"NCT03301168","lead_sponsor":"Bellicum Pharmaceuticals","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CaspaCIDe DLI (rimiducid activated rivogenlecleucel) • rimiducid (AP1903)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 04/01/2014","start_date":" 04/01/2014","primary_txt":" Primary completion: 05/11/2021","primary_completion_date":" 05/11/2021","study_txt":" Completion: 05/01/2034","study_completion_date":" 05/01/2034","last_update_posted":"2022-07-12"},{"id":"773a0191-6552-426c-b8bb-0477e9718c29","acronym":"","url":"https://clinicaltrials.gov/study/NCT02477878","created_at":"2021-01-18T11:55:57.064Z","updated_at":"2024-07-02T16:36:07.467Z","phase":"Phase 1","brief_title":"Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant","source_id_and_acronym":"NCT02477878","lead_sponsor":"Bellicum Pharmaceuticals","biomarkers":" HLA-DRB1 • HLA-B","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CaspaCIDe DLI (rimiducid activated rivogenlecleucel) • rimiducid (AP1903)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 07/01/2016","start_date":" 07/01/2016","primary_txt":" Primary completion: 01/14/2020","primary_completion_date":" 01/14/2020","study_txt":" Completion: 01/01/2033","study_completion_date":" 01/01/2033","last_update_posted":"2022-07-12"},{"id":"8f85763f-e649-4c88-96b6-c0ae0f05eac2","acronym":"","url":"https://clinicaltrials.gov/study/NCT01744223","created_at":"2021-01-18T07:37:40.124Z","updated_at":"2024-07-02T16:36:07.432Z","phase":"Phase 1/2","brief_title":"Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant","source_id_and_acronym":"NCT01744223","lead_sponsor":"Bellicum Pharmaceuticals","biomarkers":" FLT3 • KMT2A • HLA-DRB1 • HLA-B","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement • Chr t(9;11)","tags":["FLT3 • KMT2A • HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement • Chr t(9;11)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CaspaCIDe DLI (rimiducid activated rivogenlecleucel) • rimiducid (AP1903)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 03/01/2013","start_date":" 03/01/2013","primary_txt":" Primary completion: 10/09/2019","primary_completion_date":" 10/09/2019","study_txt":" Completion: 10/01/2032","study_completion_date":" 10/01/2032","last_update_posted":"2022-07-12"},{"id":"b105d23b-a787-4c0a-81db-551a2e374a07","acronym":"","url":"https://clinicaltrials.gov/study/NCT03459170","created_at":"2021-01-18T17:03:10.004Z","updated_at":"2024-07-02T16:36:07.436Z","phase":"Phase 1","brief_title":"Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant","source_id_and_acronym":"NCT03459170","lead_sponsor":"Bellicum Pharmaceuticals","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CaspaCIDe DLI (rimiducid activated rivogenlecleucel) • rimiducid (AP1903)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 02/01/2018","start_date":" 02/01/2018","primary_txt":" Primary completion: 09/01/2022","primary_completion_date":" 09/01/2022","study_txt":" Completion: 09/01/2035","study_completion_date":" 09/01/2035","last_update_posted":"2022-07-12"},{"id":"e55e829f-1588-409f-9b4c-28cbc4742a1f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03594162","created_at":"2021-01-18T17:40:22.654Z","updated_at":"2024-07-02T16:36:19.881Z","phase":"","brief_title":"Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch","source_id_and_acronym":"NCT03594162","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" CD19","pipe":" | ","alterations":" CD19 positive • CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous • iC9-CAR19 cells • rimiducid (AP1903)"],"overall_status":"No Longer Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2021-12-03"},{"id":"9e72d219-f74b-4c5d-ba34-f05984c3935d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03958656","created_at":"2021-09-09T17:53:47.480Z","updated_at":"2024-07-02T16:36:24.633Z","phase":"Phase 1","brief_title":"T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma","source_id_and_acronym":"NCT03958656","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" SLAMF7","pipe":"","alterations":" ","tags":["SLAMF7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Anti-SLAMF7 CAR T cells • rimiducid (AP1903)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 06/13/2019","start_date":" 06/13/2019","primary_txt":" Primary completion: 10/13/2020","primary_completion_date":" 10/13/2020","study_txt":" Completion: 01/19/2021","study_completion_date":" 01/19/2021","last_update_posted":"2021-09-09"},{"id":"4553806e-e0c4-4db4-ab84-19a652b71c6b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02786485","created_at":"2021-01-18T13:40:12.832Z","updated_at":"2024-07-02T16:36:40.372Z","phase":"Phase 1","brief_title":"Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT","source_id_and_acronym":"NCT02786485","lead_sponsor":"Bellicum Pharmaceuticals","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CaspaCIDe DLI (rimiducid activated rivogenlecleucel) • rimiducid (AP1903)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/01/2016","start_date":" 05/01/2016","primary_txt":" Primary completion: 12/01/2018","primary_completion_date":" 12/01/2018","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2020-10-05"},{"id":"837927b2-eb6b-4652-92eb-3c2283ccc219","acronym":"","url":"https://clinicaltrials.gov/study/NCT02487459","created_at":"2021-01-18T11:58:41.219Z","updated_at":"2024-07-02T16:36:40.421Z","phase":"Phase 1/2","brief_title":"Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies","source_id_and_acronym":"NCT02487459","lead_sponsor":"Bellicum Pharmaceuticals","biomarkers":" FLT3 • KMT2A • HLA-DRB1 • HLA-B","pipe":" | ","alterations":" FLT3 mutation • MLL rearrangement • Chr del(5q) • Chr del(7q)","tags":["FLT3 • KMT2A • HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • MLL rearrangement • Chr del(5q) • Chr del(7q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CaspaCIDe DLI (rimiducid activated rivogenlecleucel) • rimiducid (AP1903)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/01/2016","start_date":" 07/01/2016","primary_txt":" Primary completion: 06/01/2017","primary_completion_date":" 06/01/2017","study_txt":" Completion: 06/01/2017","study_completion_date":" 06/01/2017","last_update_posted":"2020-10-05"},{"id":"510d6f44-a072-43a1-b8bd-ade22d9eb8d2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03807063","created_at":"2021-01-18T18:48:54.843Z","updated_at":"2024-07-02T16:36:41.993Z","phase":"Phase 1","brief_title":"Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant","source_id_and_acronym":"NCT03807063","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":" | ","alterations":" MLL rearrangement","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CaspaCIDe DLI (rimiducid activated rivogenlecleucel) • rimiducid (AP1903)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/02/2020","start_date":" 01/02/2020","primary_txt":" Primary completion: 12/31/2020","primary_completion_date":" 12/31/2020","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2020-08-14"}]